Picture Berlin Partner Top News EIC Accelerator Noah Labs MyoPax 650x100px

Document › Details

Ryvu Therapeutics S.A.. (12/8/22). "Press Release: Ryvu Therapeutics Initiates Public Offering of Shares [not for US, AU, CA, et al.]". Krakow.

	Organisation	Ryvu Therapeutics S.A. (WSE: RVU)
	Organisation 2	BioNTech SE (Nasdaq: BNTX)
	Group	BioNTech (Group)
	Product	RVU120 (Ryvu) (formerly SEL120 (Selvita))
	Product 2	investment banking
	Index term	Ryvu Therapeutics–SEVERAL: investment, 202212 public offering PLN250.3m of 4.8m Series J common shares led by BioNTech
	Index term 2	Ryvu Therapeutics–BioNTech: investment, 202212 public offering totalling PLN250.3m incl PLN94m (€20m) from lead investor BioNTech related to collab
	Person	Przewiezlikowski, Pawel (Selvita 201309 CEO + Co-Founder)

Original document
accessed by [iito] on 2022-12-22

Record changed: 2024-01-06

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

More documents for Ryvu Therapeutics S.A. (WSE: RVU)

[1] Ryvu Therapeutics S.A.. (2/25/25). "Press Release: Ryvu Therapeutics Announces Strategic Reorganization to Extend the Cash Runway for the Development of RVU120 and the Preclinical Pipeline". Krakow....
[2] Ryvu Therapeutics S.A.. (2/19/25). "Press Release: Ryvu Therapeutics Awarded Two Grants to Support Next-generation ADCs development ". Krakow....
[3] Ryvu Therapeutics S.A.. (10/29/24). "Press Release: Ryvu Therapeutics to Collaborate with nCage Therapeutics on the Development of a Next-Generation ADC Platform". Krakow....
[4] Ryvu Therapeutics S.A.. (12/22/22). "Press Release: Ryvu Therapeutics Announces Closing of Equity Offering with Gross Proceeds over PLN 250 Million". Krakow....
[5] BioNTech SE. (11/30/22). "Press Release: BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates". Mainz & Krakow....
[6] Ryvu Therapeutics S.A.. (8/17/22). "Press Release: EIB to Support Ryvu Therapeutics’ Discovery, Research and Development of New Cancer Treatments with €22 Million"....
[7] Ryvu Therapeutics S.A.. (7/26/22). "Press Release: Ryvu Therapeutics Announces Promotion of Hendrik Nogai and Vatnak Vat-Ho to the Management Board". Kraków....
[8] Ryvu Therapeutics S.A.. (7/7/22). "Press Release: Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies". Alameda, CA & Krakow....
[9] Ryvu Therapeutics S.A.. (3/15/22). "Press Release: Ryvu Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update". Krakow....
[10] Ryvu Therapeutics S.A.. (12/14/21). "Press Release: Ryvu Announces Option to License Inflammation Program Exercised by Galapagos NV". Tübingen, Houston, TX & New York, NY....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]